Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?

cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three year results. J Natl Cancer Inst 92: 699-708, 2000 19. Stanislaus R, Carey M, Deus HF, et al: RPPAML/RIMS: A metadata format and an information management system for reverse phase protein arrays. BMC Bioinformatics 9:555, 2008 20. Zhang L, Wei Q, Mao L, et al: Serial dilution curve: A new method for analysis of reverse phase protein array data. Bioinformatics 25:650-654, 2009 21. Wong KK, Tsang YTM, Zu Z, et al: Insulin growth factor 1 pathway is a potential therapeutic target for low-grade ovarian cancers. Gynecol Oncol (in press) 22. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007 23. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 24. Ahmed A, Le XF, Lu Z, et al. Kinase regulated microtubule stabilization correlates with paclitaxel response in a target specific siRNA kinome screen. Proc Am Assoc Cancer Res 50, 2009 (abstr 3869) 25. Ahmed A, Jacomo RO, Lu Z, et al: The salt inducible kinase 2 (SIK2) is required for centrosome separation at the onset of mitosis. Proc Am Assoc Cancer Res 50, 2009 (abstr LB-43) 26. Ahmed AA, Le X-F, Lu Z, et al: Loss of CDK5 sensitizes cells to paclitaxel by enhancing intracellular retention. Proc Am Assoc Cancer Res 57, 2010 (abstr 1585) 27. Whitehurst AW, Bodemann BO, Cardenas J, et al: Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446:815-819, 2007 28. Landen CN Jr, Chavez-Reyes A, Bucana C, et al: Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910-6918, 2005